Every Thursday we send out a curated newsletter on all things femtech and women’s health innovation. This is an excerpt from the latest edition. If you’d like to subscribe, you can do so at the bottom of this page.

“Conditions that disproportionately and differently affect women have traditionally been underfunded in proportion to its burden on human health. Freya’s initial focus is on the millions of couples around the world who are struggling with infertility. This funding enables us to advance our groundbreaking immunotherapy platform targeting the vaginal microbiota and unlock its therapeutic potential in this area and beyond.” Colleen Acosta, CEO of Freya Biosciences


Freya Biosciences secures $38M in Series A funding to advance women’s reproductive immunotherapies.

Aditxt enters women’s health market with $100MEvofem acquisition.

Maya Oncology secures $4.25M to reinvent cancer care with an initial focus on breast cancer.

Pulmonary embolism startup Flow Medical adds $2M in funding.

Period pain relief brand Somedays acquires cycle care B-Corp Aisle.

iamawareacquiresBinx Health‘s consumer testing business, expanding its reach in STI health screening.

Pelvital introduces its incontinence treatment Flyte in the Middle East.

MysteryVibe launches OOH vibrator advertising campaign in a UK first.

OOVA launches perimenopause hormone kit with estrogen biomarker and real-time data tracking app.

Bone Health Technologies receives new patent for its wearable treatment for osteoporosis in post-menopausal women.

In the Know

Femtech Investment Round-up November 2023 (Femtech Insider)

The Vaginal Microbiome May Affect Health More than We Thought (Scientific America)

Our Everyday Gear Can Now Perform Tests from Home (Well + Good)

The proactive fertility care industry is soaring. Is that a good thing? (BBC)

Our ongoing fertility crisis is leading to a future where only the rich can reproduce (Salon)

Endometriosis: It’s time to change the pattern of barriers to diagnosis and treatment (The Conversation)

Show CommentsClose Comments

Leave a comment